Interleukin-1 receptor antagonist (IL-1ra) as a probe and as a treatment for IL-1 mediated disease

The natural human IL-1 receptor antagonist (IL-1ra) has been produced in a recombinant organism and has been used to study IL-1 action in vivo. The receptor antagonist mitigates the pathophysiology associated with animal models of ulcerative colitis through reducing IL-1 mediated neutrophil recruitment into the affected tissue. It also reduces joint swelling and damage in an animal model of rheumatoid arthritis, possibly by reducing IL-1 mediated synthesis of proteases by the synovial fibroblasts and chondrocytes of the joint. The receptor antagonist is not immunosuppressive in rodents, indicating that it is working by blocking the inflammatory reaction rather than any underlying defect in specific immunity.